Back to News
Market Impact: 0.2
Average Analyst Price Target for Unicycive Therapeutics Rises 12.32% to $32.54
Source: Nasdaq
Analyst EstimatesAnalyst InsightsHealthcare & Biotech
The average one-year analyst price target for Unicycive Therapeutics (NASDAQCM: UNCY) was revised up 12.32% to $32.54 per share from $28.97, with the prior estimate dated September 29, 2026. The figures are aggregate analyst targets, not a recommendation.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
UNCY0.25
More News
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Oncologists Cheer Melanoma Data
- SpaceX bear flips to big bull because of AI business. Analyst now sees 70% gain
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- Williams Trading cuts Deckers Outdoor stock price target on weak DTC trends
- Investing.com’s stocks of the week
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Capital Intensity as Gravity: The AI Trade Enters Its Industrial Era (Looking at Q3 2025 Earnings in Tech)
- AI Portfolio Monitoring: Build an Alert Policy Analysts Can Audit